Houston's innovation ecosystem development is highly interconnected to the city's real estate industry. Shobeir Ansari/Getty Images

As the city and multiple entities strive to develop an innovation hub and ecosystem, real estate plays a huge role. Developing the physical space is one of the first steps to attracting companies, talent, and money to the Bayou City.

At Bisnow's annual Houston State of the Market event, five panelists heavily involved in the process of developing Houston's innovation ecosystem weighed in on the real estate needs of innovation development in Houston. Check out these powerful quotes said during the panel.

“What we build in Houston has to be uniquely Houston. ... At the end of the day, for this innovation district and Houston’s innovation ecosystem to be successful, it has to build off of the economic strength that Houston already has."

— Ceci Arreola, investment manager of real estate at the Rice Management Company. Arreola describes a collaborative effort to make Houston somewhere attractive for tech and startup talent.

“Think of it as a neighborhood of knowledge. That’s what we’re trying to create, and that’s connecting intellectual assets, institutional assets, place assets — meaning the physical space in which people connect and relate.”

— Jonathan Brinsden, CEO of Midway Cos., describes the innovation district, which will stretch from midtown to downtown.

"The flexibility in hospitality — that sort of different version of work and play — is critically important to the entrepreneurs. They need the ability to be transient. … They want the furnished apartment, but they don’t want to live in a hotel. They want a bike lane, because they aren’t going to have a car."

— Gabriella Rowe, CEO of Station Houston, says stressing the importance of a innovation center having restaurants and retail surrounding coworking spaces. "They want to continue the conversation they're having but with a beer in their hand."

“These companies take a lot from our designs and our way of nurturing them, but they want to give back and stay within the innovation campus. I think we need to be mindful of that. There’s a lot of cross pollination that happens when companies at different levels of each stage stay together.”

— Juliana Garaizar, director of the TMC Venture Fund, stresses the importance of designing real estate that can keep companies and startups of different sizes and stages together.

“When I lived in New York City, grocery shopping was the single biggest headache I had to deal with every week. One of the things I love about Houston is that this is no longer a problem for me.”

— Chris Turney, head of real estate for Sonder, says about ensuring development of city spaces keeps in mind day-to-day conveniences that make Houston more comfortable than other major cities.

GreenStreet will soon have coworking space and a gym from Life Time. Courtesy of Midway Cos.

Life Time to open a new coworking space and fitness club in downtown Houston

Work — then work out

Life Time has announced its second Houston location of its coworking concept, Life Time Work, before it's even opened the first. Life Time will open an athletic club and coworking space in GreenStreet in downtown Houston. Houston's first Life Time Work in CITYCENTRE, which was announced last year, is expected to open in May.

"GreenStreet aligns well with our vision to meet the changing needs of consumers by bringing Life Time — through our athletic destinations and coworking space — as a lifestyle asset to bustling and successful developments," says Parham Javaheri, Minnesota-based Life Time's executive vice president of real estate and development, in a release. "We look forward to becoming an anchor to this new model of urban living in 2020."

Opening by 2020, the new location will be at 1201 Main Street and will have more than 56,000 square feet of wellness space and more than 38,000 square feet of coworking space.

"Being able to attract and retain workers who place a premium on work/life balance sets a company's culture apart," says Fernando Urrutia, vice president for Lionstone Investments, which owns GreenStreet, in the release. "Combining GreenStreet's state-of-the-art work environment with the highest level of health and wellness amenities, in the middle of downtown's expanding variety of new residential developments, will be a game-changer."

Both CITYCENTRE and GreenStreet are operated by Houston-based Midway Cos.

"We are happy Life Time has selected another Midway development after our successful collaboration at CITYCENTRE," says Chris Seckinger, vice president and investment manager for Midway, in a release. "Life Time adds an all-important healthy living component to GreenStreet, a mixed-use district that is being redeveloped as the new model of urban lifestyle. "

Midway also recently announced that Spaces, an international coworking space company, will open new locations in Houston, and the company chose CITYCENTRE and GreenStreet as two of the locations for their Houston expansion. Additionally, MassChallenge Texas announced its Houston accelerator program will operate out of GreenStreet.

Health and business

Courtesy of Midway Cos.

GreenStreet will soon have more than 56,000 square feet of wellness space and more than 38,000 square feet of coworking space from Life Time.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.